| Date | Title | Description |
| 04.11.2024 | +++ Ride +++ bao +++ Aignostics +++ neoshare +++ Series-A +++ | Was gibt’s Neues? In unserem #StartupTicker liefern wir eine kompakte Übersicht über die wichtigsten Startup-Nachrichten des Tages (Montag, 4. November) #STARTUPLAND: LEARN, CONNECT, GROW
Kommt mit ins Startupland! Es erwartet Euch eine fas... |
| 03.11.2024 | Aignostics: $34 Million (Series B) Raised To Turn Complex Pathology Data Into Transformative Insights | Aignostics – a global AI company that turns complex multi-modal pathology data into transformative insights – announced that it has raised $34 million in Series B financing. This additional funding will be used for building new product offe... |
| 29.10.2024 | Aignostics: Pioneering AI in Precision Medicine with $34 Million Boost | Aignostics, a Berlin-based artificial intelligence (AI) company, has secured $34 million in Series B funding. This significant investment is a testament to the growing confidence in AI's role in transforming healthcare. The funding round wa... |
| 29.10.2024 | Berlin-based Aignostics secures €31.4 million Series B to enhance precision medicine with AI | Aignostics, a global artificial intelligence (AI) company that turns complex multi-modal pathology data into transformative insights, announced that it has raised €31.4 million in Series B financing. This additional funding will be used to ... |
| 29.10.2024 | Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI | Investments will support new product offerings, US expansion, and development of pathology foundation models.
Aignostics, a global artificial intelligence (AI) company that turns complex multi-modal pathology data into transformative insigh... |
| 17.10.2024 | Mars Petcare's Leadership Shake-Up: A New Era for Veterinary Health and Diagnostics | In a bold move, Mars Petcare has reshuffled its leadership deck, signaling a fresh chapter for its Veterinary Health and Science & Diagnostics divisions. This change comes as the company, a titan in the pet care industry, seeks to innov... |
| 16.10.2024 | USD 8M and a strategic partner for Ikerian AG |
Ikerian AG and its subsidiary, RetinAI U.S. Inc. are committed to revolutionizing the way ophthalmology clinics connect and manage patient data. Established in 2017, the company develops software solutions to accelerate clinical, research ... |
| 16.10.2024 | Ikerian Holds Series B Funding First Close of USD 8M | (left) Carlos Ciller, PhD, CEO, co-founder and Chairman Ikerian AG and RetinAI US Inc.; (center) Stefanos Apostolopoulos, PhD, CTO and co-founder Ikerian AG and RetinAI US Inc.; (right) Sandro De Zanet, PhD, Chief Scientific Officer and co-... |
| 15.10.2024 | BioStock: Saniona achieves milestone with Boehringer Ingelheim | BioStock: Saniona achieves milestone with Boehringer Ingelheim
Tue, Oct 15, 2024 11:19 CET Report this content
Saniona’s collaboration with Boehringer Ingelheim has advanced to the lead optimization stage, triggering a 500,000 Euro research... |
| 09.10.2024 | Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment | INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–October 9, 2024–
Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal to develop a first-in-cla... |
| 08.10.2024 | Eldico secures fresh funding to fuel global expansion |
Founded in 2019 and based at the Switzerland Innovation Park Innovaare at the Paul Scherrer Institute, ELDICO has quickly established itself as a leader in electron diffraction. The company's flagship product, the ELDICO ED-1 electron diff... |
| 19.09.2024 | A New Dawn in Kidney Cancer Treatment: Roswell Park's Breakthrough Regimen | In the realm of cancer treatment, hope often flickers like a candle in the dark. But recent findings from Roswell Park Comprehensive Cancer Center have ignited a brighter flame for patients battling metastatic kidney cancer. At the European... |
| 19.09.2024 | 2024 ISPE Pharma 4.0™ and Annex 1 Conference Featured Speakers Are Announced | The 2024 ISPE Pharma 4.0™ and Annex 1 Conference will take place on 10-11 December in Rome, Italy, and virtually.
The 2024 ISPE Pharma 4.0™ and Annex 1 Conference will take place on 10-11 December in Rome, Italy, and virtually.
NORTH BETHES... |
| 18.09.2024 | Tech Park Basel zieht Bilanz |
Der Tech Park Basel ist seit Sommer 2011 in Betrieb. Neben den auf die Nutzung durch junge Technologieunternehmen zugeschnittenen Büro- und Laborflächen stellt der Tech Park Basel auch verschiedene Infrastrukturen bereit und bietet Dienstl... |
| 16.09.2024 | Positive clinical progress in the biotech scene |
With the dosing of its first patient for lead candidate CDR404, CDR-Life has made significant clinical progress in its M-gager® portfolio for solid tumors, marking important milestones in the company’s mission to deliver innovative, antibo... |
| 12.09.2024 | Revolutionizing Kidney Health: The Power of Technology and Community Engagement | Chronic kidney disease (CKD) is a silent predator, lurking in the shadows of public health. It affects over 35 million Americans, yet 90% remain unaware of their condition. The statistics are staggering: one in three adults is at risk, yet ... |
| 11.09.2024 | Study Conducted at Sheppard Pratt Reveals Lower Cognitive Functioning as Key Risk Factor for Natural Cause Mortality in Schizophrenia | BALTIMORE, Sept. 11, 2024 /PRNewswire/ -- JAMA Network Open recently published a first-of-its-kind study conducted at Sheppard Pratt identifying lower cognitive functioning as a significant risk factor for natural cause mortality among indi... |
| 10.09.2024 | Healthy.io, Geisinger and Boehringer Ingelheim Reveal Milestone Data at AHA 2024 | The collaboration's research demonstrates how smartphone technology achieved a 2.5x increase in testing rates, offering a promising solution for early CKD identification
BOSTON, Sept. 10, 2024 /PRNewswire/ -- In a leap forward for chronic k... |
| 04.09.2024 | The New Frontier in Breastfeeding Ethics: A Framework for Change | In a world where health interventions often clash with ethical considerations, a new framework emerges to bridge the gap. The University of Zurich and the Family Larsson-Rosenquist Foundation have unveiled a groundbreaking tool aimed at ass... |
| 04.09.2024 | Blue Matter Hires New Principal, John Bonasera, Expanding Capabilities in Organizational Strategy and Effectiveness | NEW YORK, Sept. 4, 2024 /PRNewswire/ -- Blue Matter is pleased to announce that it has hired John Bonasera as a Principal in its New York office. John officially joined the firm on September 3 and will play a key role in helping to expand t... |
| 04.09.2024 | Saiba Animal Health joins Boehringer Ingelheim |
Saiba Animal Health’s innovative technology platform uses a first-of-its-kind, patented therapeutic vaccine platform, designed to create an immune response, targeting chronic diseases such as allergy, inflammation and pain. The therapeutic... |
| 27.08.2024 | Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio | RIDGEFIELD, Conn., Aug. 27, 2024 /PRNewswire/ --
Data from the Phase Ib Beamion LUNG-1 trial selected for late-breaking oral presentation in the Presidential Symposium at WCLC on Monday, September 9.
The U.S. FDA and China's CDE have grante... |
| 22.08.2024 | AbbVie’s SKYRIZI[®] (risankizumab) Is Recommended by NICE as an Option for Use in Adults with Moderately to Severely Active Ulcerative Colitis | AbbVie’s SKYRIZI[®] (risankizumab) Is Recommended by NICE as an Option for Use in Adults with Moderately to Severely Active Ulcerative Colitis
Thu, Aug 22, 2024 16:04 CET Report this content
For UK consumer, medical and trade media only
In ... |
| 07.08.2024 | Healthcare And AI Sectors Continue To Lead, While Funding Settles In July 2024 | 6 Shares Email Facebook Twitter LinkedIn
Venture funding reached over $23 billion in July 2024, slightly down month over month and up more than 20% year over year, based on an analysis of Crunchbase data.
The largest funding in July went to... |
| 06.08.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies ... |
| 05.08.2024 | QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER | Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Ph... |
| 05.08.2024 | QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER | Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Ph... |
| 29.07.2024 | Boehringer Ingelheim buys Nerio Therapeutic for $1.3B | Nerio will help Boehringer to develop its preclinical immune program
Immune checkpoint blockade (ICB) is a treatment for cancer that involves the use of drugs, called immune checkpoint inhibitors (ICIs), to strengthen the immune system and ... |
| 08.07.2024 | BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial | SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-bli... |
| 27.06.2024 | The Harris Poll Announces Sponsorship of the 20th Anniversary Pharma PR & Communications Summit | The Stagwell (STGW) agency will share guidance for communicators during the 2024 election cycle
NEW YORK, June 27, 2024 /PRNewswire/ -- The Harris Poll is once again sponsoring the Fierce Pharma PR & Communications Summit, the premier e... |
| 03.06.2024 | Beghou Consulting strengthens omnichannel and customer engagement capabilities with addition of new Partners | Beghou Consulting supports the end-to-end life sciences brand lifecycle with a blend of deep domain knowledge, data science and advanced analytics expertise, and powerful technology.
To help clients drive meaningful and differentiated engag... |
| 03.06.2024 | New Program Helps COPD and Asthma Patients Afford Their Medicine | (BPT) - For many patients, a diagnosis of chronic obstructive pulmonary disease (COPD) can come as a shock. COPD, a chronic respiratory condition, can drastically impact quality of life, making everyday tasks like walking or climbing stairs... |
| 02.06.2024 | Delaware judge allows more than 70,000 Zantac lawsuits to go forward | - |
| 01.06.2024 | Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients | Boehringer's first-of-its-kind program automatically reduces the costs of its COPD and asthma inhalers at the pharmacy counter for vast majority of eligible patients
Program provides predictable, affordable and consistent costs for as many ... |
| 01.06.2024 | Centre, states gear up to tackle infectious zoonotic disease outbreaks | - |
| 29.05.2024 | Frost & Sullivan Reported The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-scale Production of Biologics | SHANGHAI, May 29, 2024 /PRNewswire/ -- Recently, Frost & Sullivan released the report "The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-scale Production of Biologics".
I. CDMOs are advancing the bi... |
| 03.05.2024 | ArisGlobal Revolutionizes Safety Signal Processing for Boehringer Ingelheim | LifeSphere Clarity redefines safety signal analysis for pharmaceutical giant Boehringer Ingelheim, setting a new standard in patient safety and risk management.
In the fast-paced world of pharmaceuticals, innovation is key. ArisGlobal, a le... |
| 03.05.2024 | Patients on hunt for diabetes, obesity and weight-loss drugs | - |
| 02.05.2024 | ELRIG UK announces Profs Ijeoma Uchegbu and Marcus Schindler as Keynote Speakers at Drug Discovery 2024 | Drug Discovery 2024: Connecting Minds, Transforming Science, Empowering Community will take place at ExCeL London from 2–3 October
Cambridge, UK - The European Laboratory Research & Innovation Group (ELRIG) UK, a not-for-profit, volunte... |
| 01.05.2024 | ArisGlobal Helps Boehringer Ingelheim Transform Safety Signal Processing by Leveraging Latest LifeSphere Solutions | LifeSphere Clarity drives efficiencies and reinvents the way Boehringer Ingelheim's pharmaceutical operations approach safety signals
BOSTON, May 1, 2024 /PRNewswire/ -- ArisGlobal, a market leader in Life Sciences technology and the creato... |
| 01.05.2024 | US FDA approves high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm) injection, Boehringer Ingelheim's interchangeable* biosimilar to Humira® | RIDGEFIELD, Conn., May 1, 2024 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), the company's ... |
| 01.05.2024 | ArisGlobal Helps Boehringer Ingelheim Transform Safety Signal Processing by Leveraging Latest LifeSphere Solutions | LifeSphere Clarity drives efficiencies and reinvents the way Boehringer Ingelheim's pharmaceutical operations approach safety signals
BOSTON, May 1, 2024 /PRNewswire/ -- ArisGlobal, a market leader in Life Sciences technology and the creato... |
| 30.04.2024 | Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum | Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance.
Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; submission of mirikizumab for Crohn's di... |
| 27.04.2024 | India becoming attractive for clinical trials, says pharma industry leaders | - |
| 24.04.2024 | Pharma exports rise around 10% to $27.9 billion, US biggest importer | - |
| 03.04.2024 | Biden touts inhaler price drops with Bernie Sanders: "Finally, finally we beat big Pharma" | Sen. Bernie Sanders and President Biden joined forces Wednesday at the White House, championing the progress they've made on lowering the cost of inhalers and other expenses for Americans with asthma.
Mr. Biden and Sanders also called on Co... |
| 29.03.2024 | Health | Experts say Medicaid rebate change is behind inhaler price cuts | Lauren Clason | (TNS) CQ-Roll Call
A recent tweak to a Medicaid formula could be behind the shake-up to inhaler products, a series of changes that have both benefited and harmed patients with asthma and chronic obstructive pulmonary disease... |
| 25.03.2024 | Veeva Vault EDC Surpasses 1,000 Study Start Milestone | Eight of the top 20 biopharmas standardize on Vault EDC to build a modern clinical data foundation
SINGAPORE, March 25, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more than 1,000 study start... |
| 21.03.2024 | Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Leading scientific, IT, and business innovators in the biopharma industry showca... |
| 20.03.2024 | Startup Lands $150M for Delicate Dance Between Cancer Cells & Immune Cells | Cancer immunotherapy comes in several forms, and one area of growing research interest is a type of drug called a T cell engager. These drugs bind to a cancer cell and a T cell simultaneously, bringing both of them together to spark a thera... |
| 13.03.2024 | Equine Healthcare Market: Galloping Growth Ahead | The equine healthcare market is set to soar to new heights, with a projected growth rate of 6.2% reaching $1.81 billion by 2028. The market is driven by a surge in awareness of animal healthcare, with North America leading the charge. Major... |
| 11.03.2024 | Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia | - |
| 11.03.2024 | Equine Healthcare Market Size, Share And Growth Analysis For 2024-2033 | Equine Healthcare Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033
The Business... |
| 11.03.2024 | Global Brucellosis Vaccine Market Worth $421 Million by 2034 - Subunit Vaccines Lead Innovation as DNA Vaccines Gain Momentum, Cattle Segment Dominates with Rapid Growth Expected in Small Ruminants | - |
| 08.03.2024 | Equine Healthcare Market Size, Share And Growth Analysis For 2024-2033 | The Business Research Company's Equine Healthcare Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033
The Business Research Company's Equine Healthcare Global Market Report 2024 – Market Size, Trends, And Global F... |
| 07.03.2024 | Veterinary CRO & CDMO Market is expected to Grow with a CAGR of 9.6% from 2024 to 2031 | - |
| 19.01.2024 | Top Employer 2024 certification reflects Boehringer Ingelheim Vietnam's impactful people development | HO CHI MINH CITY, Vietnam, Jan. 19, 2024 /PRNewswire/ -- For the fifth consecutive year, Boehringer Ingelheim Vietnam, a biopharmaceutical company focused on research, has received recognition for its exceptional workplace.
Globally, Boehri... |
| 18.01.2024 | Top Employer 2024 certification reflects Boehringer Ingelheim's impactful people development in Thailand | Boehringer Ingelheim recognized as one of 17 Top Employers worldwide and for the sixth consecutive year in Thailand
High scores in development and steering (strategy and leadership) practices highlight Boehringer Ingelheim's continued commi... |
| 18.01.2024 | Top Employer 2024 certification reflects Boehringer Ingelheim's impactful people development in Malaysia | Boehringer Ingelheim recognized as one of 17 Top Employers worldwide and for the sixth consecutive year in Malaysia
High scores in development and steering (strategy and leadership) practices highlight Boehringer Ingelheim's continued commi... |
| 18.01.2024 | Top Employer 2024 certification reflects Boehringer Ingelheim's impactful people development in Indonesia | Boehringer Ingelheim recognized as one of 17 Top Employers worldwide and for the sixth consecutive year in Indonesia
High scores in development and steering (strategy and leadership) practices highlight Boehringer Ingelheim's continued comm... |
| 18.01.2024 | Top Employer 2024 certification reflects Boehringer Ingelheim's impactful people development in Asia Pacific | Boehringer Ingelheim is recognized as one of 17 Top Employers worldwide and for the fifth consecutive year in Asia Pacific
High scores in development and steering (strategy and leadership) practices highlight Boehringer Ingelheim's continue... |
| 15.01.2024 | Active Pharmaceutical Ingredients Market To Reach USD 346.4 Billion By 2032 at CAGR 8.7%| DataHorizzon Research | Active pharmaceutical ingredients market to undergo added efficiency and transformation.
Colorado, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The Active Pharmaceutical Ingredients (API) Market size was valued at USD 151.2 Billion in 2022 and is expe... |
| 28.11.2023 | IBM and Boehringer Ingelheim Partner on Generative AI for Transformative Antibody Therapeutics | What You Should Know:
– Boehringer Ingelheim and IBM announced a collaboration to leverage IBM’s foundation model technologies for the discovery of novel candidate antibodies in drug development.
– The partnership will focus on utilizing IB... |
| 02.11.2023 | 日本ベーリンガーインゲルハイム、第32回Pneumo Forum受賞者を発表 | • 日本ベーリンガーインゲルハイムは、Pneumo Forum（ニューモフォーラム）を主催し、慢性呼吸器疾患研究の進展と研究者育成を支援
• 2023年10月28日（土）に、第32回Pneumo Forumを開催し、Pneumo Forum賞の受賞者を決定
2023年11月2日 日本／東京
日本ベーリンガーインゲルハイム株式会社（東京都品川区、代表取締役 医薬事業ユニット統括社長：荻村 正孝、以下、「日本ベーリンガーインゲルハイム」）は、2023年10月28日に、「第3... |
| 01.11.2023 | ベーリンガーインゲルハイム研究助成プログラム 助成金交付対象者決定 | 公益財団法人 日本糖尿病財団 （東京都文京区、理事長：岩本安彦 以下「日本糖尿病財団」）と日本ベーリンガーインゲルハイム株式会社（東京都品川区、代表取締役 医薬事業ユニット統括社長：荻村 正孝、以下、「日本ベーリンガーインゲルハイム」）は、本年7月1日から8月31日までの応募期間で募集していたベーリンガーインゲルハイム研究助成プログラムの助成金交付対象者が日本糖尿病財団選考委員会により選考され、理事会において決定されたことをお知らせ致します。
ベーリンガーインゲルハイム研究... |
| 03.08.2023 | CDR Life obtains milestone payment | |
| 06.02.2023 | Boehringer Ingelheim Philippines is awarded Top Employer for the 5th year in a row | Boehringer Ingelheim is one of 15 global Top Employers worldwide
Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute®
Outstanding employer benefits with emphasis on wellbeing, attractive w... |
| 19.01.2023 | Bringing out the best in people, with innovative development and well-being programmes | Growth doesn’t have to take place only in a conference room or classroom. To develop her leadership skills, Ms Catherine Ng flew to Kenya for a week as part of Boehringer Ingelheim’s Making More Health Insights programme, a global leadershi... |
| 18.01.2023 | Boehringer Ingelheim Indonesia Honored As Top Employer For The Fourth Consecutive Year | Boehringer Ingelheim is one of 15 global Top Employers worldwide
Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute®
Outstanding employer benefits with emphasis on wellbeing, attractive w... |
| 18.01.2023 | Boehringer Ingelheim Thailand Honored As Top Employer For The Fifth Consecutive Year | Boehringer Ingelheim is one of 15 global Top Employers worldwide
Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute®
Outstanding employer benefits with emphasis on wellbeing, attractive w... |
| 18.01.2023 | Boehringer Ingelheim Malaysia Honored As Top Employer For The Fifth Consecutive Year | Boehringer Ingelheim is one of 15 global Top Employers worldwide
Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute®
Outstanding employer benefits with emphasis on wellbeing, attractive w... |
| 18.01.2023 | Mental health focus makes Boehringer Ingelheim stand out as Top Employer 2023 in Asia Pacific for Third Consecutive Year | Boehringer Ingelheim is one of 15 global Top Employers worldwide
Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute®
Outstanding employer benefits with emphasis on wellbeing, attractive w... |
| 04.11.2022 | EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney diseas... | EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice1,2,3 Phase III trial also demonstrated a 14% statistically significant re... |
| 29.09.2022 | BOEHRINGER INGELHEIM DONATES NEARLY 100,000 PET VACCINE DOSES TO HELP ELIMINATE RABIES AROUND THE WORLD WITH RELAUNCH OF SHOTS FOR GOOD(SM) INITIATIVE | In recognition of World Rabies Day on September 28, the donation is for use on tribal lands and underserved communities in collaboration with Greater Good Charities
DULUTH, Ga., Sept. 28, 2022 /PRNewswire/ -- Boehringer Ingelheim, a global ... |
| 29.09.2022 | CLIMATE CHANGE AND HEALTH INEQUITY A DEADLY MIX FOR THE MOST VULNERABLE: WORLD HEART FEDERATION | GENEVA, Sept. 29, 2022 /PRNewswire/ -- On World Heart Day, the World Heart Federation (WHF) is calling for urgent action on climate change and health inequity, saying millions more lives are now at risk from cardiovascular disease, which is... |
| 25.08.2022 | The world comes to Iowa to connect, learn and innovate | This sponsored article has been published in partnership with America’s Cultivation Corridor.
As thousands of farmers and ag industry professionals descend on Boone, Iowa, for the 2022 Farm Progress Show, Iowa’s leadership in the ag industr... |
| 15.06.2022 | Boehringer Ingelheim Signs Option to Acquire Trutino Biosciences | Boehringer Ingelheim signed an option to acquire Trutino Biosciences Inc., a San Diego-based biotech company.
Led by Phillip Kim, Ph.D., MBA, Founder and CEO, Trutino Biosciences is a pre-clinical stage biotech company dedicated to the disc... |
| 03.06.2022 | Boehringer Ingelheim inks deal for targeted cancer antibodies from Singapore research org | As Boehringer Ingelheim looks to build out its efforts in oncology, its latest deal will turn toward Singapore.
The German pharma announced Thursday that it has signed a global licensing agreement with the Singapore-base... |
| 20.04.2022 | More about Gov. Kemp: Boehringer Ingelheim Expands Global Innovation Capabilities, Invests $57 Million in Athens | Atlanta, GA – Governor Brian P. Kemp today announced that Boehringer Ingelheim, a global research-driven pharmaceutical development and manufacturing company based in Germany, will expand its Animal Health Global Innovation center in Athens... |
| 20.04.2022 | Gov. Kemp: Boehringer Ingelheim Expands Global Innovation Capabilities, Invests $57 Million in Athens | GEORGIA, April 20 - Atlanta, GA – Governor Brian P. Kemp today announced that Boehringer Ingelheim, a global research-driven pharmaceutical development and manufacturing company based in Germany, will expand its Animal Health Global Innovat... |
| 05.04.2022 | Good business performance gives Boehringer Ingelheim tailwind for investment in R&D | 1. R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
2. More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years
3. Human Pharma pipeline acceleration: up to ... |
| 05.04.2022 | Good business performance gives Boehringer Ingelheim tailwind for investment in R&D | R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years
Human Pharma pipeline acceleration: up to 15 new pr... |
| 05.04.2022 | Good business performance gives Boehringer Ingelheim tailwind for investment in R&D | · R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
· More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years
· Human Pharma pipeline acceleration: up to 15 ... |
| 29.03.2022 | Nippon Beringer Ingelheim Utilization of real-world data reveals the prevalence and prevalence of systemic scleroderma (SSc) in Japan and interstitial lung disease (SSc-ILD) associated with systemic s... | Japan Boehringer Ingelheim
Utilization of real-world data reveals prevalence and prevalence of systemic scleroderma (SSc) and interstitial lung disease (SSc-ILD) associated with systemic scleroderma in Japan [1]
…………………………………………………………………………... |
| 01.03.2022 | Lifebit and Boehringer Ingelheim announce partnership to capture transformational value of health data | Boehringer Ingelheim partners with Lifebit Biotech, Ltd. to build a scalable data, analytics, and infrastructure platform
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximi... |
| 07.02.2022 | Endeavor snags $101M to go after Boehringer, Roche in lung scarring—and do some asset shopping | Endeavor Biomedicines wants to best the two idiopathic pulmonary fibrosis (IPF) drugs on the market by going after the so-called Hedgehog pathway—what it calls the "root cause" of the disease—and now it has $101 million in new fun... |
| 07.02.2022 | Endeavor snags $101M to go after Boehringer, Roche in lung scarring—and do some asset shopping | Endeavor Biomedicines wants to best the two idiopathic pulmonary fibrosis (IPF) drugs on the market by going after the so-called Hedgehog pathway—what it calls the "root cause" of the disease—and now it has $101 million in new fun... |
| 20.01.2022 | Award: Boehringer Ingelheim is Global Top Employer 2022 | Boehringer Ingelheim advances to one of eleven global top employers worldwide
This is the second consecutive year for the global certification, and the third consecutive year for the certification in Indonesia
High scores in values, ethics ... |
| 20.01.2022 | Award: Boehringer Ingelheim is Global Top Employer 2022 | Boehringer Ingelheim advances to one of eleven global top employers worldwide
This is the second consecutive year for the global certification, and the fourth consecutive year for the certification in Thailand
High scores in values, ethics ... |
| 20.01.2022 | Award: Boehringer Ingelheim is Global Top Employer 2022 | Boehringer Ingelheim advances to one of eleven global top employers worldwide
This is the second consecutive year for the global certification, and the fourth consecutive year for the certification in Philippines
High scores in values, ethi... |
| 20.01.2022 | Award: Boehringer Ingelheim is Global Top Employer 2022 | Boehringer Ingelheim advances to one of eleven global top employers worldwide
This is the second consecutive year for the global certification, and the fifth consecutive year for the certification in Singapore
High scores in values, ethics ... |
| 20.01.2022 | Award: Boehringer Ingelheim is Global Top Employer 2022 | Boehringer Ingelheim advances to one of eleven global top employers worldwide
This is the second consecutive year for the global certification, and the fourth consecutive year for the certification in Malaysia
High scores in values, ethics ... |
| 20.01.2022 | Award: Boehringer Ingelheim is Global Top Employer 2022 | Boehringer Ingelheim advances to one of eleven global top employers worldwide
This is the second consecutive year for the global certification, and the second consecutive year for the certification in Australia & New Zealand
High scores... |
| 20.01.2022 | Award: Boehringer Ingelheim is Global Top Employer 2022 | Boehringer Ingelheim advances to one of eleven global top employers worldwide
This is the second consecutive year for the global certification, and the third consecutive year for the certification in Vietnam
High scores in values, ethics an... |
| 15.12.2021 | Composer makes music to calm pets — says that even if you find a song soothing, they probably don't | Janet Marlow.
Courtesy of Janet Marlow
Janet Marlow is a performer and composer with a unique audience: pets.
Marlow began making music for animals 20 years ago after realising she could calm her pets with it.
Doing so helps Marlow pair a l... |
| 11.11.2021 | US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction | RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 11, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Jardiance® (empagliflozin) 10 mg, which is... |
| 27.10.2021 | GSK brings Johns Hopkins prof and Blade co-founder on board; Evotec sets terms for $575M+ US IPO | GlaxoSmithKline CEO Emma Walmsley is adding another scientist to the company’s board. Early Wednesday — alongside their Q3 update — Walmsley put out word that Harry “Hal” Dietz, a professor of genetics and medicine... |
| 21.10.2021 | Exclusive: Athira CEO Leen Kawas resigns after investigation finds she manipulated data | Six years ago, Boehringer Ingelheim announced that a new manufacturing plant focused on large-scale cell culture technology would be erected in Vienna, marking the largest investment in the company’s history. Last week, the site became oper... |
| 19.10.2021 | Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis | Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis
Oxford, UK – 19 October 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a lea... |
| 19.10.2021 | Sage, Biogen head to FDA with $3.1B depression drug; Sana puts down $50M to tap Beam's CRISPR tech | Weeks after announcing they would drop a pair of studies deemed unnecessary to file the depression drug zuranolone for approval, Sage and Biogen are going for it.
Following a pre-NDA meeting with the FDA, the partners say ... |
